Tango Therapeutics, Inc.
He is working on precision oncology to develop new drugs targeting the deficiencies of cancer suppressor genes in patients with high unmet medical needs. He is working on the development of small molecule compounds such as TNG908, which are designed to selectively act on cancer cells that lack specific cancer suppressor genes, killing the cancer cells while remaining relatively inactive on normal cells. He is a Delaware resident.
Overview
Overview | |
|---|---|
Country | United States |
State | Massachusetts |
Employees | 140 |
Founded | 2014 |
Financials | |
|---|---|
Market Capitalization | 1.06B |
Revenue | 37.23M |
Operating Income | -126.14M |
Operating Margin | -338.80% |
Net Income | -111.65M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4894 / 5373 |
Sector : Healthcare | 936 / 1144 |
Industry : Biotechnology | 491 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 2413 / 5565 |
Sector : Healthcare | 309 / 1182 |
Industry : Biotechnology | 123 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4812 / 5436 |
Sector : Healthcare | 917 / 1164 |
Industry : Biotechnology | 482 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3791 / 5330 |
Sector : Healthcare | 546 / 1174 |
Industry : Biotechnology | 196 / 667 |